Correlation Between Evoke Pharma and Intracellular

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Evoke Pharma and Intracellular at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Evoke Pharma and Intracellular into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Evoke Pharma and Intracellular Th, you can compare the effects of market volatilities on Evoke Pharma and Intracellular and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Evoke Pharma with a short position of Intracellular. Check out your portfolio center. Please also check ongoing floating volatility patterns of Evoke Pharma and Intracellular.

Diversification Opportunities for Evoke Pharma and Intracellular

-0.28
  Correlation Coefficient

Very good diversification

The 3 months correlation between Evoke and Intracellular is -0.28. Overlapping area represents the amount of risk that can be diversified away by holding Evoke Pharma and Intracellular Th in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Intracellular Th and Evoke Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Evoke Pharma are associated (or correlated) with Intracellular. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Intracellular Th has no effect on the direction of Evoke Pharma i.e., Evoke Pharma and Intracellular go up and down completely randomly.

Pair Corralation between Evoke Pharma and Intracellular

Given the investment horizon of 90 days Evoke Pharma is expected to under-perform the Intracellular. In addition to that, Evoke Pharma is 1.02 times more volatile than Intracellular Th. It trades about -0.05 of its total potential returns per unit of risk. Intracellular Th is currently generating about 0.15 per unit of volatility. If you would invest  8,654  in Intracellular Th on November 1, 2024 and sell it today you would earn a total of  4,046  from holding Intracellular Th or generate 46.75% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Evoke Pharma  vs.  Intracellular Th

 Performance 
       Timeline  
Evoke Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Evoke Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in March 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Intracellular Th 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Intracellular Th are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite fairly uncertain fundamental indicators, Intracellular demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Evoke Pharma and Intracellular Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Evoke Pharma and Intracellular

The main advantage of trading using opposite Evoke Pharma and Intracellular positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Evoke Pharma position performs unexpectedly, Intracellular can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Intracellular will offset losses from the drop in Intracellular's long position.
The idea behind Evoke Pharma and Intracellular Th pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Complementary Tools

Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency